skipping – Talk Bio

Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA

2 months ago talkbio0Tagged Approved, Avidity, Biosciences, Blackfoot language, Breakthrough Therapy, Clinical Trials, Functional, Improvements, Muscular Dystrophy, Duchenne, skipping, Submission, United States Food and Drug Administration

Avidity Biosciences; del-zota; DMD; Duchenne muscular dystrophy; FDA approval; functional improvements; exon 44 skipping; Breakthrough Therapy; clinical trial; BLA submission

Wave Life Sciences’ WVE-N531 Shows Promise in Duchenne Muscular Dystrophy Treatment

7 months ago talkbio0Tagged Approved, Dystrophin, Gene Expression, Health Improvement, Muscle Tissue, Muscular Dystrophy, Duchenne, Phase 2 Clinical Trials, skipping, United States Food and Drug Administration, WVE-N531

Duchenne muscular dystrophy (DMD), WVE-N531, exon 53 skipping, Phase II trial, dystrophin expression, muscle health improvement, FDA approval

Avidity’s Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment

7 months ago talkbio0Tagged Creatine Kinase, Del-zota, DMD, Dystrophin, exon, Muscular Dystrophy, Duchenne, production, RNA, safety profile, skipping

Del-zota, Duchenne muscular dystrophy (DMD), RNA therapeutics, exon 44 skipping, dystrophin production, creatine kinase reduction, safety profile

FDA Lifts Clinical Hold on Entrada’s Duchenne Muscular Dystrophy Drug ENTR-601-44 After Two Years

8 months ago talkbio0Tagged ELEVATE-44, ENTR-601, Entrada, exon, Muscular Dystrophy, Duchenne, Phase 1b Trial, skipping, Study on Hold, United States Food and Drug Administration

Duchenne muscular dystrophy, ENTR-601-44, Entrada Therapeutics, FDA, clinical hold, exon 44 skipping, ELEVATE-44-102, Phase 1b trial